Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project—Part 1)
Michèle Beau‐Faller, Armelle Degeorges, Estelle Rolland et al. · Journal of Thoracic Oncology · 2011
Cited by 56 works. doi:10.1097/jto.0b013e318211dcee
Authors
- Michèle Beau‐Faller
- Armelle Degeorges
- Estelle Rolland
- Mounia Mounawar
- Martine Antoine
- Virginie Poulot
- Audrey Mauguen
- Véronique Dorine Barbu
- Florence Coulet
- Jean‐Luc Prétet
- Ivan Bièche
- Hélène Blons
- Jean-Christophe Boyer
- Marie‐Pierre Buisine
- Florence de Fraipont
- Sarab Lizard
- Sylviane Olschwang
- Patrick Saulnier
- Delphine Mirebeau‐Prunier
- Nicolas Richard
References
- Statistical Methods for Rates and Proportions
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Cancer incidence, mortality and prevalence worldwide
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
- Epidermal growth factor receptor mutations in lung cancer
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- A One-Way Components of Variance Model for Categorical Data